Transplant indications are increasing but the availability of organs is not sufficient to meet all the needs. Many patients awaiting transplantation die.
Biofabrication will make up for the shortage of organs.
Animal drug testing is extremely expensive and ethically contested and the development of new molecules is very long and uncertain. Mini organs on a chip will allow testing directly on human biological material and will reduce costs and delays.
Biofabrication will facilitate the production of new drugs.